Home > Press > Harris & Harris Group reports net asset value
Harris & Harris Group reports net asset value
August 17, 2005
The Company announced that in connection with a proposed public
offering of shares of common stock pursuant to an effective shelf
registration statement filed with the Securities and Exchange
Commission, as of today we have determined that our net asset value
per share is $5.07. The increase of $7,952,716 in our net asset
value since our most recently reported balance sheet data as of June
30, 2005, reflects an increase of $10,715,910 in the value of our
shares in NeuroMetrix, Inc. (Nasdaq: NURO), minus an increase of
$2,160,792 in our reserve for employee profit-sharing. For the
purpose of the accrual, we calculate 20 percent of qualifying income
pursuant to the terms of the profit-sharing plan and estimate the
effect on qualifying income of selling all the portfolio investments
that are valued above cost (i.e., are in an unrealized appreciation
position). This methodology results in a fluctuation in our accrual
but is not reflective of actual payments made under the profit-
sharing plan. Profit-sharing plan payments require the existence of
qualifying income and consider only realized gains and losses
(unrealized gains are excluded.
Because our 1,137,570 shares of NURO, which went public in July
2004, are currently our most highly valued holding, the volatility
of NURO's stock price is now a significant influence on our net
asset value. NURO closed on August 16, 2005, at $29.45 per share,
versus $20.03 per share on June 30, 2005.
About Harris & Harris Group:
Harris & Harris Group is a publicly traded venture capital company
that makes initial investments exclusively in tiny technology,
including nanotechnology, microsystems and microelectromechanical
systems (MEMS). The Company's last 24 initial private equity
investments have been in tiny-technology enabled companies. As of
today, the Company has 17,248,845 shares of common stock
outstanding.
For more information, please visit www.TinyTechVC.com
Contact:Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||